Moderna begins testing its vaccine in babies and young children – Times of India

[ad_1]

Read More/Less


The drug company Moderna has begun a study that will test its Covid vaccine in children under 12, including babies as young as six months, the company said on Tuesday.

The study is expected to enroll 6,750 healthy children in the United States and Canada. Moderna declined to say how many had already signed up or received the first shots, according to a spokeswoman, Colleen Hussey.

“There’s a huge demand to find out about vaccinating kids and what it does,” said Dr. David Wohl, the medical director of the vaccine clinic at the University of North Carolina, who is not involved the study.

In a separate study, Moderna is testing its vaccine in 3,000 children ages 12 to 17, and may have results for that age group by summer. The vaccine would then have to be authorized for use in children, so it would not be immediately available.

Many parents want protection for their children, and vaccinating children should help to produce the herd immunity considered crucial to stopping the pandemic. The American Academy of Pediatrics has called for expansion of vaccine trials to include children.

Vaccine side effects like fever, sore arms, fatigue and achy joints and muscles can be more intense in children than in adults, and doctors say it is important for parents to know what to expect after their children are inoculated.

Each child in Moderna’s study will receive two shots, 28 days apart. The study will have two parts. In the first, children aged 2 years to less than 12 may receive two doses of 50 or 100 micrograms each. Those under 2 years may receive two shots of 25, 50 or 100 micrograms. (One adult dose is 100 micrograms.)

In each group, the first children inoculated will receive the lowest doses and will be monitored for reactions before later participants are given higher doses.

Then, researchers will perform an interim analysis to determine which dose is safest and most likely to be protective for each age group.

Children in part 2 of the study will receive the doses selected by the analysis — or placebo shots consisting of salt water.

Moderna developed its vaccine in collaboration with the National Institute of Allergy and Infectious Diseases. The company and the institute are also working together on the study, along with the federal Biomedical Advanced Research and Development Authority.

The children will be followed for a year, to look for side effects and measure antibody levels that will help researchers determine whether the vaccine appears to provide protection. The antibody levels will be the main indicator, but the researchers will also look for coronavirus infections, with or without symptoms.

Dr. Wohl said the study appeared well designed and likely to be efficient, but he questioned why the children were to be followed for only one year, when adults in Moderna’s study are followed for two years. He also said he was somewhat surprised to see the vaccine being tested in children so young this soon.

“Should we learn first what happens in the older kids before we go to the really young kids?” Dr. Wohl asked. Most young children do not become very ill from Covid, he said, though some develop a severe inflammatory syndrome that can be life threatening.

Johnson & Johnson has also said it would test its coronavirus vaccine in babies and young children after testing it first in older children.

Pfizer and BioNTech are testing their vaccine in children ages 12 to 15, and have said the plan is to move to younger groups; the product is already authorized for use in those 16 and up in the United States.

Last month, AstraZeneca began testing its vaccine in Britain in children 6 years and older.

[ad_2]

READ FULL ARTICLE HERE

Your Health Insurance Premium is Likely to Increase from April, Here’s Why

[ad_1]

Read More/Less


Health insurance companies are likely to hike the insurance premium by 10 per cent starting April 1. (Image by Shutterstock/Representational)

Health insurance companies are likely to hike the insurance premium by 10 per cent starting April 1. (Image by Shutterstock/Representational)

Insurance companies have received claims worth Rs 14 thousand crores, out of which companies have settled Rs 9 thousand crores.

  • Trending Desk New Delhi
  • Last Updated:March 17, 2021, 11:36 IST
  • FOLLOW US ON:

Health insurance companies are likely to hike the insurance premium by 10 per cent starting April 1. The companies had kept the premiums unchanged keeping in mind the coronavirus pandemic.

The pandemic has highlighted the need to have sufficient health and life insurance cover. High hospitalisation costs during the pandemic forced many to take tough decisions of choosing between their loved ones and the future of their families. Having the proper coverage can help in many life situations.

But, with the increase in coronavirus claims worth thousands of crores and the Insurance Regulatory and Development Authority of India (IRDAI) standard rules, the companies are forced to hike the prices.

Most companies revise premiums at the beginning of the new financial year. In such a situation, the companies are allowed to revise the premium of health insurance policy from April 1.

What led to this rise?

The insurance regulator has included many serious diseases in the medical insurance policy such as mental problems, genetic diseases, neuro-related disorders, and psychological diseases. Therefore, the inclusion of these serious illnesses is bound to increase the premium.

Another reason is the coronavirus claim of thousands of crores which is adding an additional burden on the companies and the recovery for the same will be done by increasing the premium. Insurance companies have received claims worth Rs 14 thousand crores, out of which companies have settled Rs 9 thousand crores. An increase in medical costs will also lead to a higher premium.

Meanwhile, if you are unhappy with your health insurance policy’s features or premium or insurer’s claim settlement record or benefits, then you can switch to another insurer without losing benefits. Up until early 2011, portability of health insurance was not an option, but it was the insurance regulatory IRDAI that introduced the portability norms, giving policyholders the choice to switch insurers.

[ad_2]

READ FULL ARTICLE HERE

Coronavirus Vaccine: Do you have full protection immediately after vaccination? And other things you should know | The Times of India

[ad_1]

Read More/Less


The COVID vaccine shot can certainly prevent you from the many complications associated by the virus that’s still surging across the globe. However, if you think the jab would also suffice complete protection against the newer, deadlier COVID strain, there’s something you should know.

Even with the best vaccine shot, there still would be a marginal chance that one can get infected with the virus.

With the newer coronavirus strains in circulation, there still exists a high risk of infection. However, as scientists are observing, there may be a difference in the way you develop symptoms.

Here are some things you need to know before getting prepped up for your vaccination turn.

[ad_2]

READ FULL ARTICLE HERE

Coronavirus News LIVE Updates: PM Modi to Meet CMs on Covid-19 Situation, Vaccine Drive as Cases Spike; States on Alert Amid Second Wave Fears

[ad_1]

Read More/Less


Coronavirus News LIVE Updates: Prime Minister Narendra Modi will hold a video conference with chief ministers today to assess the Covid-19 situation in the country as well as the vaccination drive amid a spike in active cases that has increased the government’s worry. PM Modi’s last interaction with chief ministers was in January before the vaccination roll-out. He had announced that the Centre will bear the expenses of vaccinating nearly three crore healthcare and frontline workers in the first round and suggested that public representatives, a reference to politicians, should not be part of this initial exercise.

The announcement comes in the backdrop of states such as Maharashtra, Punjab, Karnataka, Gujarat and Tamil Nadu continuing to report a surge in Covid-19 daily cases, accounting for 78.41 per cent of the new cases, the Union Health Ministry said. Fifteen of the 19 districts in India with the highest number of coronavirus cases in the last ten days are in Maharashtra, which is grappling with an alarming spike in Covid cases. The state is “in the beginning of a second wave of Covid,” the Centre told the Uddhav Thackeray-led government. According to government data, nearly 1,000 new cases have been registered every day for the past ten days in Pune, Nagpur, and Mumbai. Nagpur, which is lockdown for a week since Monday, has seen 20,104 cases in the last ten days, compared to Pune’s 26,218 and Mumbai’s 11,859 in the same time.

The 19 districts with the highest number of coronavirus cases are Pune with 26,218 cases; Nagpur with 20,104; Mumbai with 11,859; Thane with 10,914; Nashik with 9,024; Aurangabad with 6,652; Jalgaon with 6,598; Indore with 5,238; Bengaluru Urban with 5,047; Amravati with 4,250; Ahmednagar with 3,962; Chennai with 3,811; Mumbai suburban with 3,355; Yavatmal with 3,326; Akola with 3,299; Buldhana with 3,185; Nanded with 3,146; Wardha with 2,431; and Jalandhar with 2,424, said a report by NDTV.

[ad_2]

READ FULL ARTICLE HERE

Parliamentary panel flags under-utilisation of funds given in pandemic

[ad_1]

Read More/Less


The Parliamentary Standing Committee on Labour has raised concerns over the Labour and Employment Ministry missing physical targets for schemes and asked the Ministry to look into why it was unable to use funds allocated to it, particularly during the pandemic, in an optimal way.

In its report on the demand for grants for 2021-2022 that was presented in Parliament on Tuesday, the panel said: “The Committee also desires that the Ministry seriously look into the infrastructural or procedural constraints impeding optimal utilisation of funds especially made available during the pandemic (sic).”

The report said there had been an increase in the allocation for the Ministry from ₹12,065.49 crore in the Budget Estimate (BE) to ₹13,719.56 crore in the Revised Estimate (RE) in 2020-2021 due to the launch of the Pradhan Mantri Gareeb Kalyan Yojana (PMGKY) during the pandemic to boost the economy.

“The Committee notes that though an allocation of ₹4,860 crore has been made for the PMGKY in the First Supplementary Demand for Grants, only ₹2,566 crore could be spent as on 15.02.2021, which amounts to utilisation of only 52.8% of the funds. Further, there has been a downward revision of the allocation for the scheme to ₹2,600 crore at the RE Stage. This apart, ₹1,000 crore has been allocated for Atmanirbhar Bharat Rojgar Yojana (ABRY) at RE stage,” the report said.

While ₹1,000 crore was allocated for the ABRY scheme in 2020-2021 at the time of the second supplementary demand for grants, the utilisation of funds stood at “nil due to non-dispersal of funds”.

The report said the Ministry had not utilised funds in an even manner over the four quarters of the current financial year.

“The Committee also observes that gross underutilisation of funds has impacted the performance of certain schemes thereby defeating the laudable intent of these schemes in benefiting the targeted group. The Committee, therefore, exhorts upon the Ministry to act on improving the implementation machinery and work towards bringing about more efficiency, especially during these critical times. (sic).”

The panel said it was ‘concerned’ that the Ministry had not been able to meet physical targets in many major schemes. The main cause of this was the pandemic, it said. While some schemes, like the coaching-cum-guidance centres for the SCs/STs, had achieved the targets, others, like the training centres for working children and the Pradhan Mantri Shram Yogi Maan-Dhan Yojana, which achieved 1.18 lakh enrolments out of the target of 2 crore new enrolments, had not.

“The Committee, while acknowledging the fact that the pandemic may have had a deleterious effect on the implementing agencies, nevertheless, cannot help noting that the targeted beneficiaries of these schemes were also the ones who were severely hit by the pandemic (sic),” it said.

With regard to the Employees Provident Fund Organisation, the report said it was concerned about the increase in pending grievances. It said the Ministry must take steps to reduce the pending grievances from 30,411 as of the end of 2020.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

[ad_2]

READ FULL ARTICLE HERE

Today’s top business news: Stocks pare opening gains, Bitcoin falls after weekend record high as Centre considers a ban, diesel sales rise as economic activity picks up, and more

[ad_1]

Read More/Less


The Nifty and the Sensex opened the day on a  positive note to recuperate some of the losses from yesterday.

Bitcoin’s price is in the limelight after sources revealed the Centre may ban the digital currency.

Join us as we follow the top business news through the day.

4:30 PM

Rupee pares early gains, settles 9 paise lower at 72.55 against US dollar

The rupee’s gains didn’t last long.

PTI reports: “The rupee pared its initial gains and depreciated 9 paise to settle at 72.55 (provisional) against the US dollar on Tuesday as muted domestic equities and strengthening of the greenback overseas weighed on investor sentiment.

At the interbank forex market, the local unit opened at 72.46 against the American currency and witnessed an intra-day high of 72.37 and a low of 72.64.

It finally ended at 72.55, registering a fall of 9 paise over its previous closing. On Monday, the rupee had settled at 72.46.

“Indian Rupee depreciated amid strong dollar and muted domestic markets. Further, rupee slipped on disappointing macroeconomic data,” said Saif Mukadam, Research Analyst, Sharekhan by BNP Paribas.

Additionally, market remained cautious ahead of major central banks monetary policy meetings, Mukadam said.

However, sharp downside was prevented on softening of crude oil prices.

Crude oil prices slipped on concern about slow pace of vaccination in the EU after Germany, France and Italy joined other European nations to hit pause on AstraZeneca COVID-19 vaccine, Mukadam said.

Rupee may trade in the range of 72.25 to 73.00 in next couple of sessions, he added.

The dollar index, which gauges the greenback’s strength against a basket of six currencies, advanced 0.04 per cent to 91.87.

Meanwhile, Brent crude futures, the global oil benchmark, fell 1.51 per cent to USD 67.84 per barrel.

On the domestic equity market front, the BSE Sensex ended 31.12 points or 0.06 per cent lower at 50,363.96, while the broader NSE Nifty fell 19.05 points or 0.13 per cent to 14,910.45.

Foreign institutional investors were net sellers in the capital market as they offloaded shares worth Rs 1,101.35 crore on Monday, according to exchange data.”

4:00 PM

Sensex, Nifty end marginally lower; financial stocks drag

The morning gains didn’t last long for stocks.

PTI reports: “Equity benchmarks Sensex and Nifty gave up early gains to end marginally lower on Tuesday, tracking losses in financial stocks.

The 30-share BSE Sensex ended 31.12 points or 0.06 per cent lower at 50,363.96, and the broader NSE Nifty slipped 19.05 points or 0.13 per cent to 14,910.45.

L&T was the top loser in the Sensex pack, shedding 1.56 per cent, followed by ICIC Bank, SBI, Kotak Bank, HDFC Bank, NTPC, Axis Bank and Bajaj Finserv.

On the other hand, Asian Paints, Dr Reddy’s, HCL Tech, HUL and Bharti Airtel were among the gainers.

Domestic equities gave up initial gains and traded flat towards the final hours of the day despite favourable cues from global equities, said Binod Modi – Head Strategy at Reliance Securities.

“Financials once again dragged the markets. Notably, IT stocks were in focus today mainly on expectations of sustained earnings momentum in 4QFY21E and benefits from possible fall in INR.

“In our view, increasing concerns with regards to resurgence of COVID-19 cases in various parts of the country and resulted restrictions could be a near term risk for domestic markets. Additionally, volatile bond markets and soaring inflation will continue to weigh on investors’ sentiments,” he added.

Elsewhere in Asia, bourses in Shanghai, Hong Kong, Tokyo and Seoul ended on a positive note.

Stock exchanges in Europe were also trading with gains in mid-session deals.

Meanwhile, the global oil benchmark Brent crude was trading 1.61 per cent lower at USD 67.77 per barrel.”

3:30 PM

Hero Electric sells 50,000 units in 2020

Hero continues to dominate the electric segment of the market.

PTI reports: “Hero Electric on Tuesday said it has sold over 50,000 electric two-wheelers last year thus retaining the top slot in the segment.

The company further said its sales network has crossed the 600 touchpoint mark covering 500 towns and cities across the country, thus offering the widest service network offered by any brand in the segment.

“As we come out of an extremely challenging year, we at Hero Electric are extremely proud of what we have achieved. When we were faced with the situation, we had two options at hand, and I am glad we chose to fight it out with our experience and support from each and everyone connected to us. We are proud to have achieved our goals despite all challenges,” Hero Electric Chief Executive Officer Sohinder Gill said in a statement.

This year the company is looking forward to presenting an exciting lineup of products, he added.

Hero Electric, through 2021, plans to expand its Ludhiana-based manufacturing facility from an existing capacity to produce 70,000 units per year to 2.5 lakh per annum.

The company is also looking at 15 per cent sales growth in the next fiscal on the back of its hybrid sales model, a combination of online and offline sales.

The company further said it has added 1,500 new charging points through 2020-21 across various cities.”

2:00 PM

APAC not on track to achieve SDG goals by 2030; may realise 10% of target: UN report

The Asia-Pacific region lags behind in achieving the UN’s sustainable development goals.

PTI reports: “The Asia-Pacific region is lagging behind in achieving the Sustainable Development Goals (SDGs) set for 2030, and at the current rate the region may achieve less than 10 per cent of the targets, a UN report said on Tuesday.

As many as 829 million workers employed in the informal sector were impacted in April 2020 due to the pandemic-induced lockdown, the report noted.

There are 17 goals under the United Nations Economic and Social Commission for Asia and Pacific (UNESCAP), targeted to be achieved by 2030.

These include no poverty, zero hunger, good health and well being, quality education, gender equality, clean water and sanitation, affordable and clean energy, decent work and economic growth, bio-diversity, innovation and infrastructure, and reduced inequalities, among others.

“The Asia-Pacific (APAC) region is not on track to achieve any of the 17 SDGs by 2030. On its current trajectory, the region may achieve less than 10 per cent of the SDG targets,” said the report titled ‘Asia and the Pacific SDG Progress Report’ of the UNESCAP.

The region must urgently reverse its regressing trends on many SDGs to achieve its ambitions by 2030, the UN report said adding Asia-Pacific fell short of its 2020 milestones even before entering the global pandemic.

“There is therefore an added urgency to ensure that responses to the pandemic in the region and at the national level accelerate progress toward the 2030 Agenda,” it said.

The report also talks about the impact of mandatory lockdowns and social distancing measures on data collection activities, particularly from vulnerable groups.

Unemployment increased by 15 million in the region in 2020. Compared to 2019, workers in the region lost 7.1 per cent of their labour income in 2020, equivalent to over USD 1 trillion, it said.

“In April 2020, lockdown measures impacted some 829 million informal workers in Asia-Pacific region.” Acknowledging that in the last decade, Asia-Pacific made extraordinary progress in good health and well-being, credited to partly explain its relative success in reducing the health impact of COVID-19 on its people, the report said despite these hard won gains, there are challenges in providing adequate healthcare workforce, reducing premature deaths and improving mental health.

Some subregions are well positioned to achieve a few of the goals. East and North-East Asia is on track to eradicate poverty and provide clean water and sanitation for all.

South-East Asia is on track to promote sustainable industry and innovation.

However, none of the sub-regions are on track on environment-related goals, and four sub-regions are regressing on climate action and life below water.

Making an alarming observation on regressing climate action trends and life below water goals, UNESCAP said the region is responsible for more than half of the global greenhouse gas emissions and adverse impacts of natural disasters on people and economies increase year-by-year.

“As we find our way out of this pandemic, the report suggests we must focus efforts on more equitable and greener growth,” it said.

Green house gas emissions containment measures due to the pandemic resulted in a significant reduction in the hazardous emissions with a decrease in global daily carbon dioxide emissions of 17 per cent in April 2020 compared to the year-ago period.

In Asia-Pacific, this pattern has been evident in China, India, Japan and the Russian Federation.

Environmental monitoring, including satellite data clearly indicates that air quality has improved in the first half of 2020 in many countries of the region. Data shows air pollution over northern India at a 20-year low, with New Delhi and nearby areas registering a significant 50 per cent reduction of aerosol optical depth (correlating to fine particulate matter, PM2.5 and PM10) in April.

However, the report said while the drop in carbon dioxide emissions has been significant, it was also temporary and emissions rose as soon as lockdowns were lifted.

China relaxed its lockdown earlier than other countries, and the impact is particularly evident with its emissions during April to June comparable to or higher than emissions in the year-ago same months, the report pointed out.

“Recovery measures are an excellent opportunity for us to rethink our options for development pathways that are inclusive, more resilient, and respect planetary boundaries,” said United Nations Under-Secretary-General and ESCAP Executive Secretary Armida Salsiah Alisjahbana.

“As we enter the Decade of Action to deliver the 2030 Agenda for Sustainable Development, we need to reinforce our collective commitment to the SDGs and let it provide our compass for building back together, better and greener,” she said.

To build back better, governments should renew their commitments to the SDGs’ monitoring framework so that recovery can accelerate a global transformation as promised by the 2030 Agenda, the report said.

The agency has also developed a National SDG Tracker tool to help the countries in the region make progress assessment on the goals.

National governments can use the tool to produce snapshots of progress towards the ambitions of the 2030 Agenda, it said.”

1:30 PM

India’s diesel sales rise as economic activity picks up

More signs of economic recovery.

PTI reports: “Indian state fuel retailers’ diesel sales rose 7.4% to 2.84 million tonnes in the first fortnight of March from a year earlier, preliminary industry data showed on Tuesday.

Petrol sales rose 5.3% to 1.05 million tonnes in the same period from a year earlier, the data showed.

This is the first annual rise in gasoil sales in the country since October. Fuel sales in India took a hit in March last year as the government imposed a nationwide lockdown to curb the spread of the novel coronavirus.

India’s economy returned to growth in the three months to December and the recovery is expected to gather pace as consumers and investors shake off the effects of the COVID-19 pandemic.

The rise in gasoil sales, which account for about two-fifths of the country’s overall fuel demand, comes despite record-high local retail prices and points to rising industrial production in the country.

State companies Indian Oil Corp, Hindustan Petroleum Corp and Bharat Petroleum own about 90% of India’s retail fuel outlets.

State retailers sold 3.3% less cooking gas in the first half of March than a year ago to 1.01 million tonnes as a significant reduction in subsidies curtailed demand for the fuel, the data showed.

Jet fuel sales were down 36.5% to 204,000 tonnes.”

12:30 PM

Ahead of IPO, Kalyan Jewellers mobilises ₹352 crore

Kalyan Jewellers India Ltd on Monday raised ₹352 crore from anchor investors ahead of its initial share-sale, which opens for public subscription on Tuesday.

The company’ IPO committee has decided to allocate 4,04,48,275 shares at ₹87 per piece to 15 anchor investors. At this price, the firm garnered ₹351.89 crore, Kalyan Jewellers informed BSE.

The anchor investors include the Government of Singapore, Monetary Authority of Singapore, HDFC Life Insurance Co Ltd, and BNP Paribas Arbitrage.

The ₹1,175-crore initial public offer (IPO) comprises issuance of fresh equity aggregating up to ₹800 crore and an offer for sale (OFS) worth ₹375 crore.

 

12:00 PM

Twitter launches multi-lingual ‘info prompt’ ahead of Assembly elections

With Assembly elections coming up in five States, micro-blogging platform Twitter on Monday announced a dedicated ‘information search prompt’ in six languages with the Election Commission of India and State Election Commissions to tackle misinformation and provide reliable details related to elections.

The U.S.-headquartered firm has also rolled out a multilingual youth discussion series in India ‘DemocracyAdda’ aimed at driving voter literacy and civic participation among young Indians, along with a video series ‘HerPoliticalJourney’ that will focus on women political leaders.

“With the Assembly Elections 2021 taking place in Assam, Kerala, Tamil Nadu, West Bengal, and Puducherry, [We have] announced a series of initiatives focused on encouraging informed and healthy conversations between candidates, political parties, citizens, media, and society,” the company said in a statement.

 

11:30 AM

AU Small Finance Bank shares gain over 4% on fund raising 

A big mover among stocks.

PTI reports: “The stock of AU Small Finance Bank jumped over 4 per cent in early trade on Tuesday after the company said it has raised Rs 625.50 crore by issuing shares to a set of investors through qualified institutional placement (QIP).

Shares of the company gained 4.27 per cent to Rs 1,238.05 on the BSE.

At the NSE, it rose by 4.13 per cent to Rs 1,237.65.

The bank has completed the allotment of equity shares under QIP and has successfully raised Rs 625.5 crore through the issuance of 50,00,000 equity shares at an issue price of Rs 1,251 per share, the bank said in a regulatory filing on Monday.

The issue was launched on March 9, with a floor price of Rs 1,181.06 apiece.

The QIP witnessed strong reception from both domestic and international institutional investors and the QIP was subscribed by sovereign wealth funds, large foreign portfolio investors, life insurance companies and domestic mutual funds, AU Small Finance Bank said.

AU Bank intends to use the net proceeds for supporting long-term growth aligned to the bank’s internal risk appetite, to maintain sufficient headroom over and above the regulatory capital adequacy requirements; and for general corporate requirements or any other purposes, it said.”

11:00 AM

China factory output, retail sales accelerate

China’s industrial output growth quickened in January-February, beating expectations, as the vast manufacturing sector started 2021 on a firm footing and the economy consolidated its brisk recovery.

Retail sales in the period also rose in a boost to domestic demand, giving a strong lift to business activity on top of the recent upsurge in exports growth.

Industrial output rose 35.1% in the first two months, up from a 7.3% uptick seen in December, data from the National Bureau of Statistics showed on Monday. That was stronger than a median forecast of a 30% surge in a Reuters poll.

 

10:30 AM

Bitcoin falls after weekend record high as India considers a ban

A blow for bitcoin bulls.

Reuters reports: “Bitcoin dropped on Monday, falling from a record high above $60,000 over the weekend, as investors digested a potential ban from India on cryptocurrencies.

The cryptocurrency had hit a record high of $61,781.83 on Saturday after U.S. President Joe Biden signed off on his $1.9 trillion fiscal stimulus and ordered an acceleration in vaccinations.

Because some investors tend to see bitcoin as a hedge against inflation, analysts believe the rise of bitcoin has been helped by the prospects of a steep economic recovery.

In afternoon trading, bitcoin was down 5.3% at $55,865,

A senior government official told Reuters overnight that India, Asia’s third-largest economy, is preparing a bill that would criminalise possession, issuance, mining, trading and transferring crypto-assets.

The bill was in line with India’s January government agenda that called for banning private virtual currencies such as bitcoin while building a framework for its own official digital currency.

“Renewed interest from the Indian government in banning cryptocurrencies led to the initial drop from the $60,000 range down to $56,000,” said John Wu, president of AVA Labs, an open-source platform for creating financial applications using blockchain technology.

In India, despite government threats of a ban, transaction volumes are swelling and 8 million investors now hold 100 billion rupees ($1.4 billion) in crypto-investments, according to industry estimates. No official data is available.

The world’s largest virtual currency hit $61,781.83 on Saturday, rising more than 40% since late February, as investors shrugged off concerns over sky-high valuations.

Despite Monday’s pullback, many investors believe the outlook for bitcoin’s price remains tilted to the upside.

Seth Melamed, the Tokyo-based chief operating officer of cryptocurrency exchange Liquid, said legislation of the sort India is proposing will not be an impediment to further gains for bitcoin.

“Because it’s decentralized, government bans or acceptance is somewhat irrelevant,” Melamed said. “Capital will find a way.”

Bitcoin has risen more than 90% this year, broadly outperforming traditional asset classes, fuelled by the embrace of cryptocurrencies by mainstream companies and large investors, including Tesla Inc and Bank of NY Mellon.

“The reason bitcoin’s continued rise is such a surprise to the traditional financial market is because they are looking at its fundamentals, while they should be looking at the market forces driving its adoption,” said Sergey Nazarov, co-founder of Chainlink, a decentralized network that provides data to smart contracts on the blockchain.

“Bitcoin is involved in the same market dynamic as all Fiat money, where market forces determine its value much more than any kind of clear fundamentals,” he added.

Bitcoin’s record on Saturday was hit in thin markets due to the weekend, with technical factors magnifying the move higher, said Justin d’Anethan, sales manager at digital asset company Diginex in Hong Kong.”

10:00 AM

Sensex rises over 200 pts in early trade; Nifty tests 15K

Stocks bounce back after yesterday’s losses.

PTI reports: “Equity benchmark Sensex jumped over 200 points in opening trade on Tuesday, tracking gains in index majors Infosys, Reliance Industries and Asian Paints amid positive trend in global markets.

The 30-share BSE index was trading 274.03 points or 0.54 per cent higher at 50,669.11, and the broader NSE Nifty was up 75.10 points or 0.50 per cent at 15,004.60.

Asian Paints was the top gainer in the Sensex pack, rising around 2 per cent, followed by Titan, UltraTech Cement, Bharti Airtel, Infosys, Reliance Industries and M&M.

On the other hand, Bajaj Auto, NTPC and SBI were the laggards.

In the previous session, Sensex had ended 397 points or 0.78 per cent lower at 50,395.08. The broader NSE Nifty finished 101.45 points or 0.67 per cent down at 14,929.50.

Foreign institutional investors (FIIs) were net sellers in the capital market on Monday as they sold shares worth Rs 1,101.35 crore, as per exchange data.

“We are now in a highly volatile phase where the market swings on a daily basis, responding to major triggers. The major trigger now is the US bond yield which has the potential to move huge money,” said V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services.

Rising bond yield triggers selling in equity markets and when yields cool down buying resumes, he said, adding that bear hammering and short covering are making markets excessively volatile.

“Consecutive 2 days of institutional selling — by both FIIs and DIIs — weakened the Indian market. But this is not a directional trend. Post the Federal Open Market Committee (FOMC) meet and a possible affirmation of the dovish stance by the Fed, the market may resume its upward move. Presently top quality financials present a buying opportunity,” he noted.

Elsewhere in Asia, bourses in Shanghai, Hong Kong, Tokyo and Seoul were trading on a positive note in mid-session deals.

US equities too ended with gains in the overnight session.

Meanwhile, the global oil benchmark Brent crude was trading 0.83 per cent lower at USD 68.31 per barrel.”

9:30 AM

‘Indian airports may see ₹5,400 cr. net loss in FY21’

With a sharp reduction in passenger traffic, estimated at about 66% year-on-year in FY21, the airport sector in India is expected to witness a significant net loss of ₹5,400 crore and cash loss of ₹3,500 crore during the year, says ICRA.

However, the robust liquidity of the players would help the sector sail through this unprecedented times, the rating agency said in a report.

ICRA said in the next financial year the industry is likely to report net profit of ₹190 crore backed by passenger traffic recovery by 130% year-on-year.

“In FY2022, the sector is expected to witness improvement in operating income by 73% to ₹14,500 crore and net profit to ₹190 crore supported by recovery in passenger traffic by around 130% y-o-y,” the report said.

The domestic passenger traffic is expected to decline by 61% Y-o-Y and international traffic by 85% Y-o-Y in FY2021, it said.

[ad_2]

READ FULL ARTICLE HERE

Non-invasive skin swab tests can quickly detect COVID-19: study

[ad_1]

Read More/Less


The samples were collected by gently swabbing a skin area rich in sebum such as the face, neck or back

Non-invasive skin swab samples may be enough to detect the novel coronavirus quickly, according to a study published in the E Clinical Medicine journal.

Researchers at the University of Surrey in the U.K. noted that COVID-19 pandemic has led to an unprecedented demand for testing — for diagnosis and prognosis — as well as for investigation into the impact of the disease on the host metabolism.

Sampling sebum — an oily, waxy substance produced by the body’s sebaceous glands — has the potential to support both needs by looking at what the virus does to us, rather than looking for the virus itself, they said.

The most widely used approach to testing for COVID-19 requires a polymerase chain reaction (PCR) test, which involves taking a swab of the back of the throat and far inside the nose.

The researchers collected sebum samples from 67 hospitalised patients — 30 who had tested positive for COVID-19 and 37 who had tested negative. The samples were collected by gently swabbing a skin area rich in sebum such as the face, neck or back.

The team analysed the samples by using liquid chromatography mass spectrometry and a statistical modelling technique to differentiate between the COVID-19 positive and negative samples.

The researchers, including those from the Universities of Manchester and Leicester, found that patients with a positive COVID-19 test had lower lipid levels — or dyslipidemia — than their counterparts with a negative test.

They noted that the accuracy of the findings increased further when medication and additional health conditions were controlled.

“Our study suggests that we may be able to use non-invasive means to test for diseases such as COVID-19 in the future — a development which I am sure will be welcomed by all,” said Melanie Bailey, co-author of the study from the University of Surrey.

Matt Spick, co-author of the study from the University of Surrey noted that COVID-19 damages many areas of metabolism.

“In this work, we show that the skin lipidome can be added to the list, which could have implications for the skin’s barrier function, as well as being a detectable symptom of the disease itself,” Spick said.

Investigating new methods of diagnosis and surveillance in a new disease such as COVID-19 that has had such a devastating effect on the world is vital, according to George Evetts, Consultant in Anaesthesia & Intensive Care Medicine at Frimley Park Hospital. “Sebum sampling is a simple, non-invasive method that shows promise for both diagnostics and monitoring of the disease in both a healthcare and a non-healthcare setting,” Evetts added.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

[ad_2]

READ FULL ARTICLE HERE

Germany, France, Italy Suspend Use of AstraZeneca Vaccine Amid Blood Clot Reports

[ad_1]

Read More/Less


Germany, France and Italy on Monday became the latest countries to suspend use of AstraZeneca’s COVID-19 vaccine over reports of dangerous blood clots in some recipients, though the company and European regulators have said there is no evidence the shot is to blame.

ALSO READ: No Evidence Of Increased Blood Clot Risk From Vaccine, Says AstraZeneca

Germany’s health minister said the decision was taken on the advice of the country’s vaccine regulator, the Paul Ehrlich Institute, which called for further investigation into seven reported cases of clots in the brains of people who had been vaccinated.

“Today’s decision is a purely precautionary measure,” Jens Spahn said.

French President Emmanuel Macron said his country would likewise suspend shots at least until Tuesday afternoon, when the European Union’s drug regulatory agency will weigh in on the vaccine. He said France hopes to resume using the formula soon.

Italy’s medicines regulator also announced a precautionary, temporary ban.

AstraZeneca said on its website that there have been 37 reports of blood clots out of more than 17 million people vaccinated in the 27-country European Union and Britain. The drugmaker said there is no evidence the vaccine carries an increased risk of clots.

In fact, it said the incidence of clots is much lower than would be expected to occur naturally in a general population of this size and is similar to that of other licensed COVID-19 vaccines.

The European Medicines Agency and the World Health Organization have also said that the data does not suggest the vaccine caused the clots and that people should continue to be immunized.

The AstraZeneca shot has become a key tool in European countries’ efforts to vaccinate their citizens against COVID-19. But Pfizer’s and Moderna’s vaccines are also used on the continent, and Johnson & Johnson’s one-shot vaccine has been authorized but not yet delivered.

In the US, which relies on the Pfizer and Moderna vaccines, AstraZeneca is expected to apply any day now for authorization.

Blood clots can travel through the body and cause heart attacks, strokes and deadly blockages in the lungs. AstraZeneca reported 15 cases of deep vein thrombosis, or a type of clot that often develops in the legs, and 22 instances of pulmonary embolisms, or clots in the lungs.

Denmark last week became the first country to temporarily halt use of the AstraZeneca vaccine in recent days to investigate. It said one person developed clots and died 10 days after receiving at least one dose. The other countries include Ireland, Thailand, the Netherlands, Norway, Iceland, Congo and Bulgaria.

Last week, Germany and France were among the nations that stuck by the shot, while Italy suspended only a specific batch of the vaccine. Britain is standing by AstraZeneca’s vaccine for now.

Spahn, the German health minister, said of the decision to suspend the AstraZeneca shot: “The most important thing for confidence is transparency.” He said both first and second doses of the vaccine would be affected by the suspension.

German authorities have encouraged anyone who feels increasingly ill more than four days after receiving the shot — for example, with persistent headaches or dot-shaped bruises — to seek medical attention.

Germany has received slightly over 3 million doses of the AstraZeneca vaccine. Spahn said about 1.6 million doses of the shot have so far been administered in the country.



[ad_2]

READ FULL ARTICLE HERE

Antibodies raised by COVID-19 vaccine less effective against some coronavirus variants: Study – Times of India

[ad_1]

Read More/Less


According to a new study, antibodies induced by some COVID-19 vaccines are less effective at neutralising the new circulating variants of the novel coronavirus, such as the ones reported in the UK, Brazil and South Africa.

The study was published in the journal Cell and noted that the neutralising antibodies induced by the Pfizer and Moderna COVID 19 vaccines were less effective against the coronavirus variants first found in South Africa and Brazil.

As per the scientists, neutralising antibodies work by binding tightly to the virus and blocking it from entering the cells and thus preventing infection. That said, this binding only happens when the antibodies and viruses perfectly match, like a key in a lock.

If the shape of the virus changes when the antibody attaches to it, the antibody may no longer be able to recognise and neutralise the virus.

The scientists compared how well the antibodies worked against the original strain versus the new variants.

When the scientists tested the new strains against vaccine-induced neutralising antibodies, they found the three new strains first described in South Africa were 20-40 times more resistant to neutralisation.

The two strains first described in Brazil and japan were five to seven times more resistant as compared to the original SARS-CoV-2 virus lineage from Wuhan, China.

“In particular we found that mutations in a specific part of the spike protein called the receptor-binding domain were more likely to help the virus resist the neutralizing antibodies,” said one author of the study.

However, the ability of these variants to resist neutralising antibodies doesn’t mean the vaccines won’t be effective.

“The body has other methods of immune protection besides antibodies. Our findings don’t necessarily mean that vaccines won’t prevent COVID, only that the antibody portion of the immune response may have trouble recognizing some of these new variants,” said the scientists.

To develop the next generation it’s important to understand which mutations are more likely to allow the virus to evade vaccine-derived immunity.

The study can also help researchers develop more effective preventative methods, such as a broadly protective vaccine that works against a wide variety of variants, regardless of the number of mutations that develop.

[ad_2]

READ FULL ARTICLE HERE

Coronavirus updates | March 14, 2021

[ad_1]

Read More/Less


India reported its biggest daily rise this year of 25,320 Covid-19 cases on Sunday. This is the fourth day that cases have consistently risen over 20,000 infections. Until March, only twice had cases crossed 20,000 in January.

So far India has reported 11.36 million cases of which 2,07,703 cases are active infections.

The rise in infections were led by the Maharashtra, Kerala, Punjab, Karnataka, Gujarat, Tamil Nadu and Madhya Pradesh who accounted for 87.73% of new cases. Maharashtra accounted for the highest number of cases at 15,602.

India’s Covid deaths increased by 161 to 158,607 over the last 24 hours, a notable spike considering an average of about a 100 daily deaths since February.

Close to 30 million vaccine doses have been administered since the beginning of the drive on January 16 with around 1.5 million of those given between Saturday and Sunday morning, according to the latest figures from the Ministry of Health. About 1.4 million of those doses were administered in the last 24 hours.

The maximum deaths were also recorded in the States with the rising caseload with Maharashtra registering 88 fatalities followed by Punjab with 22 deaths and Kerala with 12 deaths.

You can track coronavirus cases, deaths and testing rates at the national and State levels here. A list of State Helpline numbers is available as well.

Here are the latest updates:

Chhattisgarh

C’garh govt plans to allow use of Covaxin in state: Minister

The Chhattisgarh government is considering allowing the use of Covaxin, a vaccine against COVID-19, in the state after the Centre dropped its ‘clinical trial mode’ tag, state Health Minister T.S. Singh Deo said on Sunday.

In January, Mr. Singh Deo had requested Union Health Minister Dr Harsh Vardhan to halt the supply of Covaxin, developed by Bharat Biotech, to the state until its phase-3 trials are completed and results are made available.

The Serum Institute of India (SII)-made vaccine Covishield is being used in the state as part of the vaccination drive.

Talking to PTI, Singh Deo said, “We are considering allowing Covaxin for those who wish to opt for it after the Government of India dropped the vaccine from clinical trial mode, even though the complete data of its third phase of trials is yet to be published.” The data (of phase-2 trials) of Covaxin published in the Lancet Infectious Diseases journal has indicated that its safety is not in question so now the only question pending is about its efficacy, he said.

Telangana

Telangana staying alert as cases surge in neighbouring States

Telangana Health teams in districts bordering neighbouring States are taking COVID-19 sample collection kits to people’s doorstep. Other measures such as fever survey and home isolation are being enforced to contain the resurgence of the virus.

District Medical and Health Officers (DMHO) in Kamareddy, Adilabad, and other districts said they have set up check posts, and are sending medical teams to villages as well as testing contacts of coronavirus-positive patients.

Health Minister Eatala Rajender directed officials on Friday to stay alert as COVID cases are seeing a spurt in neighbouring States.

Health officials use ICU admission of COVID-19 patients as a yardstick to measure the resurgence. ICU admissions in government and private hospitals has been hovering between 340 and 360 a day from March 1 to 12.

New Delhi

JNU to reopen reading rooms, eating joints

As part of phased reopening, Jawaharlal Nehru University (JNU) on Saturday said that reading rooms at Dr. B.R. Ambedkar Central Library and in various centres and schools, and two of the eating joints on the campus will be permitted to reopen.

A notification dated March 12 issued by the university administration read, “The reopening of ground floor reading rooms inside the Dr. B.R. Ambedkar Central Library is allowed in a phased manner. Librarian may devise standard operating preventive (SOP) measures such as mandatory wearing of the face mask and maintaining social distancing norms on library premises.”

“NSS student volunteers may be engaged to create awareness in the campus, including library premises for maintaining social distancing and wearing masks to prevent the spread of COVID-19 in the university campus,” the notice added.

Odisha

Odisha may promote students to next class

With the number of COVID-19 cases showing an upward trend in some parts of the country, the Odisha government is contemplating promoting all students from Classes 1 to 8 to the next higher classes this year.

If promoted, it will be the second consecutive class promotions for students without physically appearing for their examinations.

Last year, the State government had shut down schools due to the pandemic while the students were in the middle of the examinations.

School and Mass Education Minister Samir Ranjan Das expressed apprehension that there is remote chance of conducting physical classes for Classes 1 to 8 this year in view of the resurgence of COVID-19 cases in the country.

New Delhi

Delhi CM gives ₹1-crore compensation to family of deceased ‘corona warrior’

Chief Minister Arvind Kejriwal on Saturday provided financial assistance of ₹1 crore to the family of COVID warrior Rakesh Jain, a lab technician at Hindu Rao Hospital.

Jain, who would have retired in 2022, contracted COVID-19 on June 17 last year and succumbed to it the next day. Mr. Kejriwal commended Jain for continuing to serve the people till his last breath.

“Mr. Jain got infected while on duty. He was shifted to Metro Hospital, but died later. He was a martyr who served the people of Delhi till his last breath,” Mr. Kejriwal said.

Mr. Jain was a resident of Delhi and had joined service in 1988. He is survived by his mother Madan Shri Jain, wife Sangeeta Jain and two children.

U.K.

India’s role as world’s pharmacy phenomenal, says U.K. Minister

The role that India has played during the course of the coronavirus pandemic as the pharmacy of the world has been phenomenal, U.K. Minister Lord Tariq Ahmad said as he prepared for a five-day, five-city tour of India starting on Monday.

Lord Ahmad, the Minister for South Asia in the U.K. Foreign, Commonwealth and Development Office (FCDO), highlighted the close collaboration between the two countries on ensuring supplies of COVID-19 vaccines, which benefits countries across the globe through the United Nations-led COVAX facility.

“Our relationship with India is not just one of bilateral importance, it’s also about how these two countries are working together and there’s no better illustration than the current COVID-19 pandemic which grips us. The strong collaboration we have seen between the U.K. and India in responding across the world, including through the COVAX facility which is helping the more vulnerable countries in the world,” he said.

Karnataka

‘Duo with new strain of virus doing well’

Two persons from Ballari who tested positive for the South African strain of COVID-19 on Thursday are doing well.

Speaking to The Hindu on Saturday, Deputy Commissioner of Ballari Pavan Kumar Malapati said that both the patients were healthy and doing well.

“This is just another strain of COVID-19. All the protocols meant for handling the pandemic are strictly followed. Both the patients are healthy and doing well. As soon as they got the confirmation of being infected with the new strain, they got isolated. We are going to send their throat swab samples for repeated test to get the negativity of the disease confirmed,” he said.

Karnataka

Surge in new cases not uniform

Even though the number of new COVID-19 infections in Karnataka last week showed an increase of 1,000 cases compared to the previous week, the surge does not appear to be uniform across the State.

While Bengaluru Urban accounted for 639 cases out of the increase of 1,000 cases in the State during the week ending March 11, according to the Department of Health and Family Welfare, 10 districts reported a decline in number of cases during the week compared to the previous week while the numbers remained constant in five others.

However, 15 out of the 30 districts in the State have shown an increase in the week-on-week COVID-19 tally amid signs of an unmistakable surge in infections across the State.

The cases have shown an upward trend in Tumakuru, Mysuru, Kalaburagi, Udupi, Kolar, Ballari, Dharwad, Bidar, Uttara Kannada, Bengaluru Rural, Bagalkot, Dakshina Kannada, Gadag, and Chikkmagaluru, apart from Bengaluru Urban.

Punjab

Punjab shuts all anganwadi centres due to rising cases

Punjab Minister Aruna Chaudhary on Saturday instructed that all anganwadi centres be closed till further orders in view of the spike in COVID-19 cases in the State.

The social security, women and child development minister said ration and other material will be distributed door to door through anganwadi workers and helpers, so that nutritional support to beneficiaries is not affected.

Thirty-four more fatalities due to COVID-19 were reported in Punjab on Friday, taking the death toll to 6,030, while the infection count climbed to 1,94,753 with 1,414 new coronavirus cases in the state.

New Delhi

Ambient air pollutants contribute to spread, virulence of SARS-CoV-2 infections, says Harsh Vardhan

There is emerging evidence to suggest that exposure to ambient air pollutants, especially PM2.5 and NO2, contribute to the spread and virulence SARS-CoV-2 infections, said Health Minister Harsh Vardhan on Saturday, while inaugurated the new green campus of Indian Council of Medical Research’s (ICMR) National Institute for Research in Environmental Health (NIREH), at Bhopal.

“Furthermore, ambient air pollution is a known risk factor for multiple adverse health outcomes, including chronic cardio-respiratory morbidities, and the presence of said morbidities renders the affected population more vulnerable to COVID-19,” said the Health Minister.

To worsen matters, he added, closed indoor spaces provide ideal environments for viral transmission due to the lack of ventilation preventing the dilution of viral particles, and the absence of ultraviolet rays which can potentially inactivate the virus.

 

[ad_2]

READ FULL ARTICLE HERE

1 2 3 4 5 6 8